Low-dose botulinum toxin with ankle taping for the treatment of spastic equinovarus foot after stroke

Reiter, Frank; Danni, Maura; Lagalla, G.; Ceravolo, Maria Gabriella; Provinciali, Leandro

doi:10.1016/s0003-9993(98)90068-5

Cited by 124 publications

(74 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There is some evidence for the use of splinting/casting to enhance the effects of BTX 11,12 and also for the use of electrical stimulation 13 . For the present, specific recommendations for management must rely on clinical opinion rather than research evidence.…”

Section: What Is the Evidence That Btx Work?mentioning

confidence: 99%

Botulinum toxin in the management of spasticity in adults

Turner-Stokes

Ward²

2002

Clinical Medicine

View full text Add to dashboard Cite

-Botulinum toxin (BTX) is a powerful neurotoxin which blocks cholinergic transmission at the neuromuscular junction. Judiciously applied, it can reduce local muscle overactivity while maintaining the strength in other muscles. To date BTX has not been licensed for use in spasticity in the UK and the literature pertaining to clinical practice is still relatively scant. However, controlled trials have provided evidence of the effectiveness of BTX both in reducing spasticity itself and in achieving functional gain. The guidance given here to clinicians involved in the management of spasticity covers the types of patient suitable for treatment using BTX, the appropriate dosage, and the necessary follow-up procedures and documentation.

show abstract

Section: What Is the Evidence That Btx Work?mentioning

confidence: 99%

Botulinum toxin in the management of spasticity in adults

Turner-Stokes

Ward²

2002

Clinical Medicine

View full text Add to dashboard Cite

show abstract

“…Furthermore, 4 studies could not be included in the meta-analysis 24,25,29,31 , and their results were only described in this review. Among these 4 studies, there was no statistically significant improvement in stride length in 3 of them 24,25,29 , corroborating the results found in the meta-analysis.…”

Section: Discussionmentioning

confidence: 99%

“…Of these, 732 studies were excluded after reading the titles, 22 after reading the summaries and 5 after reading the full text. Manual search did not return any item and thus the final number of studies included in this study was 15 14,15,[19][20][21][22][23][24][25][26][27][28][29][30][31] . The main reason for exclusion of studies were: use of animals, use of medication, studies in clinical conditions other than CVA in and studies with types of intervention other than the KT.…”

Section: Characteristics Of the Included Studiesmentioning

confidence: 99%

“…In relation to meta-analysis, the effects of KT were evaluated for gait speed, step length, functional mobility and balance. Among the studies that evaluated these outcome measures, 5 that evaluated the gait speed 14,20,24,26,29 and 4 that evaluated the step length 24,25,29,31 could not be included in the meta-analysis for not having a control group or for not presenting the results of mean values found or for not reporting the variability measures. Thus, all studies included in the metaanalysis evaluated the gait speed and step length by the 10-meter walk test (7 studies), functional mobility by TUG (3 studies) and the balance by the Berg Balance Scale (5 studies).…”

Section: Effect Of Kt On the Gait Of Stroke Subjectsmentioning

confidence: 99%

“…Reiter et al 31 / 5 18 stroke patients (7 women and 11 men) with age range from 28 to 70 years old, divided into 2 groups: Group A -Botulinum toxin Group B -Botulinum toxin and KT.…”

Section: Force Platformmentioning

confidence: 99%

See 2 more Smart Citations